TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26481177
Drug: Cochlear implant
Normalized name: Cochlearia officinalis leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cochlear implant programming for 12 weeks postoperatively or after tinnitus occurrence
Study: 9446004
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid (Nevigramon) 1 tablet 3 times daily for 21.6 months
Study: 20386017
Drug: Sotrastaurin 400
Normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin 400 mg
Study: 20386017
Drug: Sotrastaurin 400
Normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotrastaurin 400 mg + Tacrolimus 7 mg
Study: 22455403
Drug: Group psychotherapy
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group psychotherapy (GPT) plus 50 mg sildenafil on-demand
Study: 25196890
Drug: Spironolactone 25
Normalized name: spironolactone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 25 mg/day
Study: 2995463
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic ointment (bacitracin, polysporin, neomycin) applied thrice daily
Study: 11408983
Drug: Triple antibiotic
Normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple antibiotic ointment
Study: 21328517
Drug: Balaglitazone 10
Normalized name: Balaglitazone
DrugBank: Balaglitazone (DB12781)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balaglitazone 10 mg
Study: 9866432
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of beta-blockers to prevent postoperative cardiac complications
Study: 8793448
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 2 mg nedocromil sodium and 100 micrograms salbutamol
Study: 23340449
Drug: DFMO+sulindac treatment
Normalized name: Sulindac
DrugBank: Sulindac (DB00605)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DFMO+sulindac treatment in dietary polyamine quartiles 1-3
Study: 18600434
Drug: 0 g
Normalized name: Co Q-10 Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 g PEG 400 (control)
Study: 10720272
Drug: Embryonic porcine
Normalized name: Secretin porcine
DrugBank: Secretin porcine (DB09527)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Embryonic porcine VM tissue treated with a monoclonal antibody directed against major histocompatibility complex class I
Study: 25573027
Drug: Sham electrical
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham electrical stimulation (SES) and conventional swallowing therapy
Study: 24516695
Drug: Flumazenil injection
Normalized name: Flumazenil Injection
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flumazenil injection immediately after endoscopy
Study: 22464118
Drug: Yoga therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga therapy
Study: 18067816
Drug: Ulinastatin infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ulinastatin infusion (6000 U/kg for 30 min, then 1000 U.kg(‐1).h(‐1) until end of operation)
Study: 3305794
Drug: Matched allogenic
Normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched allogenic bone marrow transplantation (BMT) following preparation with cyclophosphamide and fractionated total body irradiation (TBI)
Study: 29183074
Drug: FMT by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: FMT by oral capsule
Study: 140084
Drug: 1% hydrocortisone
Normalized name: HYDROCORTISONE 0.01 g in 1 g TOPICAL OINTMENT [AFASSCO 1% Hydrocortisone]
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 1% hydrocortisone cream
Study: 6089305
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg cimetidine three times daily and 400 mg at night
Study: 12171817
Drug: Oxygen inhalation
Normalized name: oxygen INHALATION GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxygen inhalation at 2 L/min
Study: 25058216
Drug: Hemoglobin transfusion
Normalized name: HEMOGLOBIN
DrugBank: Hemoglobin (DB04945)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hemoglobin transfusion threshold of 7 g/dL
Study: 12766103
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine administered before breakfast
Study: 27111084
Drug: Rivastigmine patch
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine patch monotherapy
Study: 30881102
Drug: Morphine 4
Normalized name: morphine 4 mg/mL injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 4 mg
Study: 24867603
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (HD, 6 mg.kg(‐1))
Study: 16946696
Drug: Lamotrigine monotherapy
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine monotherapy (100-200 mg/day)
Study: 16946696
Drug: Lamotrigine monotherapy
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine monotherapy with ASH as supplemental medication
Study: 16946696
Drug: Lamotrigine monotherapy
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine monotherapy with ASH vs other psychotropic medications
Study: 16946696
Drug: Lamotrigine adjunctive
Normalized name: Lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lamotrigine adjunctive therapy with ASH
Study: 6315123
Drug: Oral progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral progesterone 100 mg daily
Study: 21174129
Drug: Behavioral therapy
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral therapy (BT) sleep intervention composed of stimulus control, modified sleep restriction (MSR), relaxation therapy (RT), and sleep hygiene counseling
Study: 28735785
Drug: Separate length
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate length determination and root canal preparation (Control)
Study: 10023697
Drug: 5-fluorouracil (5-FU)
Normalized name: 5-FU
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-fluorouracil (5-FU) at 500 mg/body/day for 3 days
Study: 22475362
Drug: Direct thrombin
Normalized name: Direct thrombin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct thrombin inhibitors
Study: 29699509
Drug: Short-term fasting
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term fasting (STF) during chemotherapy
Study: 16801509
Drug: Adjusted low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adjusted low-dose warfarin
Study: 3300565
Drug: Etretinate therapy
Normalized name: etretinate
DrugBank: Etretinate (DB00926)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etretinate therapy
Study: 18840257
Drug: Baclofen in
Normalized name: baclofen Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen in combination with alcohol
Study: 16720445
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray (MFNS) 200 microg once daily (QD)
Study: 15176158
Drug: Low-dose doxycycline
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose doxycycline hyclate
Study: 1706531
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer solution (LRS)
Study: 10502592
Drug: Transmyocardial revascularization
Normalized name: ALCOHOL 80 mL in 100 mL TRANSENDOCARDIAL LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmyocardial revascularization followed by continued medical therapy
Study: 10211032
Drug: Bupivacaine 75
Normalized name: bupivacaine hydrochloride 3.75 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 75 mg in 0.9% saline 60 ml and epinephrine 5 micrograms/ml
Study: 30792988
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg efavirenz
Study: 30792988
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg efavirenz
Study: 22508376
Drug: Carbidopa 450
Normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbidopa 450 mg/day
Study: 19879596
Drug: Colesevelam 3.75
Normalized name: colesevelam 3.75 g oral powder for reconstitution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colesevelam 3.75 g/d
Study: 7770708
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole
Study: 326384
Drug: CMF chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CMF chemotherapy
Study: 9613540
Drug: Interpleural injections
Normalized name: bleomycin
DrugBank: Bleomycin (DB00290)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interpleural injections via a catheter (20 mL 0.25%, 4-6 times per day for 3-6 days; n = 25 for right, n = 12 for left)
Study: 6111295
Drug: Clemastine fumarate
Normalized name: Clemastine Fumarate
DrugBank: Clemastine (DB00283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clemastine fumarate (antihistamine H1-antagonist)
Study: 23573238
Drug: Hydroxyethyl cellulose
Normalized name: Hydroxyethyl Cellulose
DrugBank: Hydroxyethyl cellulose (DB11602)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethyl cellulose placebo gel
Study: 2299491
Drug: Biofeedback treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback treatment
Study: 22429760
Drug: Tadalafil 20
Normalized name: tadalafil 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tadalafil 20 mg as needed (PRN)
Study: 28324627
Drug: Buprenorphine induction
Normalized name: buprenorphine Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine induction and dose stabilization during hospitalization followed by post-discharge transition to office-based buprenorphine treatment (OBOT)
Study: 1587064
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg proguanil alone
Study: 1587064
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg proguanil with 100 mg racemic mephenytoin
Study: 12511310
Drug: Oral dexamethasone
Normalized name: dexamethasone Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dexamethasone (0.6 mg/kg)
Study: 19525739
Drug: Monotherapy (MT)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (MT)
Study: 19129751
Drug: EVT 301
Normalized name: EVT 201
DrugBank: EVT 201 (DB05721)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVT 301 (25 mg)
Study: 9113121
Drug: Tropisetron 5
Normalized name: tropisetron 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tropisetron 5 mg
Study: 12008682
Drug: NPH insulin
Normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPH insulin (once or twice daily)
Study: 23432755
Drug: low-level TAC
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: low-level TAC (3-7 μg/L) and high-level SIR (8-12 μg/L) (TACL/SIR(H), n=140)
Study: 9677830
Drug: Anticardiolipin antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticardiolipin antibodies (IgM)
Study: 23687231
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (group P; n = 75)
Study: 23687231
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (group P)
Study: 20139427
Drug: Vaginal levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Vaginal levonorgestrel (1.5 mg single dose on LH + 2; n = 7)
Study: 19676125
Drug: 360 microg
Normalized name: Interferon alfa-2a (as peginterferon alfa-2a) 360 microgram/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 360 microg PEG‐IFNalpha‐2a weekly plus ribavirin at 1000‐1200 mg/day for 12 weeks
Study: 19676125
Drug: 180 microg
Normalized name: Pramipexole (as pramipexole dihydrochloride) 180 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 microg PEG‐IFNalpha‐2a weekly plus ribavirin at 1000‐1200 mg/day for 12 weeks
Study: 8934728
Drug: FEC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEC with high-dose infusional 5-fluorouracil
Study: 2391398
Drug: flurbiprofen 200
Normalized name: flurbiprofen 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: flurbiprofen 200 mg plus cimetidine 300 mg qid for 7 days before and for 2 days after receiving flurbiprofen
Study: 19505968
Drug: 0.7 ml
Normalized name: ethanol 0.7 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 ml kg(‐1) of contrast material injected with a fixed duration of 10 s (Group C)
Study: 22175055
Drug: 90 mL
Normalized name: 190 ML Infugem 10 MG/ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 90 mL of sodium phosphate (NaP)
Study: 3010626
Drug: Diazepam at
Normalized name: AT 10
DrugBank: Dihydrotachysterol (DB01070)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam at 0.3 mg . kg‐1
Study: 7706572
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide inhaled at 64 vpm
Study: 7706572
Drug: Nitric oxide
Normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitric oxide inhaled at 512 vpm
Study: 29580238
Drug: Community Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Health Workers (CHWs) treatment for SAM
Study: 21029339
Drug: Aliskiren 300
Normalized name: aliskiren 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren 300 mg
Study: 8184997
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (cognitive behavioral treatment + supportive drug maintenance)
Study: 23187888
Drug: Microdose of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microdose of zidovudine (100 μg)
Study: 22664978
Drug: Ropivacaine 0.75%
Normalized name: ROPivacaine 0.75% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.75% 20 mL
Study: 23094720
Drug: Class IC
Normalized name: Antiarrhythmics, class Ic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class IC or class III antiarrhythmic agents
Study: 6619270
Drug: Carbamazepine treatment
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine treatment (3-5 weeks)
Study: 9535315
Drug: Carbamazepine treatment
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Carbamazepine treatment
Study: 26986171
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (3.7 and 4.62 GBq)
Study: 1346337
Drug: Late therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late therapy
Study: 30243957
Drug: Low-dose lipopolysaccharide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lipopolysaccharide (LPS, 0.4 ng/kg body weight)
Study: 28393342
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care program (12 weeks)
Study: 3538995
Drug: Theophylline monohydrate
Normalized name: Theophylline monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline monohydrate (281.7 mg)
Study: 3928264
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg ketoprofen
Study: 20500134
Drug: Antibiotics (amoxicillin)
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotics (amoxicillin)
Study: 7133974
Drug: Pentazocin 100
Normalized name: Pentazocine
DrugBank: Pentazocine (DB00652)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pentazocin 100 mg
Study: 10658936
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (8 mg/kg) followed by L-NMMA
Study: 2894357
Drug: Nitrendipine alone
Normalized name: nitrendipine
DrugBank: Nitrendipine (DB01054)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrendipine alone or in combination with hydrochlorothiazide or propranolol or both
Study: 31619393
Drug: Active TWO2
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TWO2 therapy
Study: 20940567
Drug: PSP clinical
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: PSP clinical pathway applied to treatment group (n = 30)
Study: 10587552
Drug: Hormonal Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormonal Replacement Therapy (HRT) - conjugated oestrogen 0.625 mg daily from day 1 to day 21 plus medroxyprogesterone acetate 5 mg daily days 10-21
Study: 25725179
Drug: Continuous low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Continuous low-dose methylprednisolone infusion
Study: 12490789
Drug: Reduced-dose CsA
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced-dose CsA plus concentration-controlled SRL (troughs 10-20 ng/mL; group B, n=100)
Study: 18324951
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg once weekly (OW)
Study: 27306581
Drug: Flunarizine 10
Normalized name: flunarizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine 10 mg/d
Study: 24948345
Drug: PTH 1-34
Normalized name: PTH 1-34
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PTH 1-34 delivered via twice-daily injection
Study: 1582305
Drug: Early adjunctive
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early adjunctive corticosteroids for Pneumocystis pneumonia
Study: 4076329
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green 0.15 mg/kg intravenously
Study: 27007392
Drug: n-3 fatty
Normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: n-3 fatty acids (4 g)
Study: 26745694
Drug: Iniparib 8
Normalized name: Iniparib
DrugBank: Iniparib (DB13877)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iniparib 8 mg/kg intravenously on days 1 and 4 weekly
Study: 25065093
Drug: 400 ml
Normalized name: Lantidra 400 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 ml 10% CHO drink preoperative night and 2 hours before anesthesia
Study: 20463641
Drug: Calcineurin inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitor (CsA)
Study: 15459842
Drug: Carbonic anhydrase
Normalized name: Carbonic anhydrase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbonic anhydrase inhibitors (n = 26)
Study: 15459842
Drug: None of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: None of these drugs (n = 258)
Study: 21769873
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid supplementation (0 mg kg(‐1))
Study: 1398851
Drug: Chloramphenicol succinate
Normalized name: Chloramphenicol succinate
DrugBank: Chloramphenicol succinate (DB07565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chloramphenicol succinate (CS) 50 mg/kg/day
Study: 9081358
Drug: Dolasetron mesilate
Normalized name: Dolasetron mesilate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dolasetron mesilate 2.4 mg/kg
Study: 11382722
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with abciximab
Study: 8023659
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural administration of 50 micrograms sufentanil
Study: 31804890
Drug: Acetazolamide (AZ)
Normalized name: Acetazolamide
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetazolamide (AZ) 500 mg/day
Study: 9852907
Drug: Adenosine 100
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine 100 mumol/L
Study: 9852907
Drug: Adenosine 50
Normalized name: adenosine 50 mcg/mL-NaCl 0.9% intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine 50 mumol/L
Study: 15177597
Drug: Nonpenetrating deep
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonpenetrating deep sclerectomy with T‐flux implant
Study: 9621483
Drug: EPI +
Normalized name: 8-epi-cyanocobalamin
DrugBank: 8-epi-Cyanocobalamin (DB14092)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPI + DEX (1,000 mg/m2 i.v.)
Study: 2650646
Drug: Sodium warfarin
Normalized name: Warfarin Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium warfarin
Study: 12519653
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg arecoline
Study: 2880447
Drug: Oral temazepam
Normalized name: Temazepam
DrugBank: Temazepam acetate (DB14671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral temazepam 20 mg